Companies › Interna Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Apo-Si-K170A-C76 small interfering RNA (siRNA) against SARS-CoV-2 | SARS-COV-2 | Phase 1 | SARS-CoV-2 (COVID-19) Infection | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07095049 | Apo-Si-K170A-C76 | Phase 1 | SARS-CoV-2 (COVID-19) Infection | Infectious disease | Jul 2025 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.